NA Proactive news snapshot: Medexus Pharmaceuticals, Pressure BioSciences, Next Green Wave, Ventura Cannabis, Biocept UPDATE … – Proactive Investors USA & Canada

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) posted fiscal first-quarter results after the bell on Thursday showing a healthy year-over-year increase in revenue and positive underlying earnings. The Montreal-based drugmaker saw its revenue in the quarter to end June 2019 jump to C$16.1 million, up from C$3.2 million in the same quarter in the prior-year.  The company also finished the quarter with cash and cash equivalents of C$27.4 million, according to its statement.

Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday that it has won two more customers for its water-soluble CBD manufacturing system, the BaroShear K45. In July, Pressure Bio announced the sale of its first BaroShear K45 system to Nano CBD Cosmetics LLC. The two new orders are from Vancouver-based NanoPeak Solutions Inc and a privately-owned company in Las Vegas, Nevada.

Next Green Wave Holdings Inc (CSE:NGW) (OTCMKTS:NXGWF) hit a new milestone this week with the successful completion of its first cannabis harvest. The Vancouver-based company said Thursday that all 14 flower rooms at the company’s California facility are stocked with plants, and six of them are in the flowering stage. The cannabis company told investors that it expects to become fully operational this month.

Ventura Cannabis and Wellness Corp (CSE:VCAN) has received the stamp of approval from regulators to close its acquisition of Kush Rush, a California dispensary and delivery service. Los Angeles-based Ventura said Thursday that the Bureau of Cannabis Control approved the acquisition, part of Ventura’s strategy to build a network of California dispensaries. Kush Rush will serve as a template for Ventura’s California dispensaries under contract or application, the company said in a statement.

Biocept Inc (NASDAQ:BIOC) announced Thursday it will tout its patented liquid biopsy technology, Target Selector, at a major lung cancer conference in Spain next month.  The San Diego’s company’s Target Selector detects and isolates cancer biomarkers such

Read More Here...

Leave a Comment

Please Rate This Content*

Your email address will not be published. Required fields are marked *

Scroll to Top